Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100280Source: DataRank Database

A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern is a research paper published in JTO Clinical and Research Reports (2022). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 3.54)OA: goldTopics (28)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Yeonjung Jo ORCID,Jonathan Chipman ORCID,Benjamin Haaland ORCID,Sonam Puri ORCID,Wallace Akerley ORCID

Live enrichment

PubMed:35243411 PMC:PMC8861643 OpenAlex:https://openalex.org/W4205912731

National Institutes of Health

Grant: P30CA042014

National Institutes of Health

Grant: 3P30CA042014-30S2

Cancer Center Support Grant

Boehringer Ingelheim

AstraZeneca

National Cancer Institute

Takeda Pharmaceutical Company

National Kidney Foundation

Janssen Pharmaceuticals

Merck

Sanofi

FWCI

3.54

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtocrr.2022.100280

publisherhttps://doi.org/10.1016/j.jtocrr.2022.100280

publisherhttps://api.elsevier.com/content/article/PII:S2666364322000054?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364322000054?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35243411

Fields of Study

Occupational and environmental lung diseasesCancer Immunotherapy and Biomarkersvaccines and immunoinformatics approaches03 medical and health sciences0302 clinical medicine

Keywords

MedicineInternal medicineHazard ratioOncologyPemetrexedMesotheliomaCohortContext (archaeology)BevacizumabPropensity score matchingChemotherapyProportional hazards modelConfidence intervalPathologyMalignant Pleural MesotheliomaOverall SurvivalMaintenance TherapySecond-line TherapyReal-world OutcomesFirst-line Platinum TherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensOriginal ArticleRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 2 of ATG5 as biomarker for early detection of malignant mesothelioma

10.6084/m9.figshare.26584647.v1figshare

Additional file 2 of ATG5 as biomarker for early detection of malignant mesothelioma

10.6084/m9.figshare.26584647figshare

Additional file 1 of ATG5 as biomarker for early detection of malignant mesothelioma

10.6084/m9.figshare.26584644.v1figshare

Additional file 1 of ATG5 as biomarker for early detection of malignant mesothelioma

10.6084/m9.figshare.26584644figshare